---
title: "Dasiglucagon"
canonical_url: https://peptidelibrary.app/library/dasiglucagon
description: "FDA-approved glucagon analog (Zegalogue) for severe hypoglycemia in people with diabetes who weigh at least 20 kg. A ready-to-use rescue injection; Drugs@FDA lists both presentations as discontinued."
updated: 2026-10-30
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Dasiglucagon

Dasiglucagon (also called Zegalogue or ZP4207) is an FDA-approved glucagon analog for severe hypoglycemia. Dasiglucagon is a glucagon receptor agonist. It activates glucagon receptors in the liver, which breaks down stored glycogen and releases glucose into the blood, so it works only if the liver has glycogen to release.

FDA-approved glucagon analog (Zegalogue) for severe hypoglycemia in people with diabetes who weigh at least 20 kg. A ready-to-use rescue injection; Drugs@FDA lists both presentations as discontinued.

Also known as: Zegalogue, ZP4207.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: FDA-approved glucagon analog for severe hypoglycemia
- Mechanism class: Glucagon Receptor Agonist
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Dasiglucagon is a glucagon receptor agonist. It activates glucagon receptors in the liver, which breaks down stored glycogen and releases glucose into the blood, so it works only if the liver has glycogen to release. It has 29 amino acids like glucagon, with seven substitutions that keep it stable in a ready-to-use solution, whereas glucagon emergency kits use a powder that has to be reconstituted.

Targets: Glucagon receptor.

Origin: Synthetic glucagon analog developed by Zealand Pharma as ZP4207.

## Properties

- Sequence: His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ala-Ala-Arg-Ala-Glu-Glu-Phe-Val-Lys-Trp-Leu-Glu-Ser-Thr
- Length: 29
- Molecular formula: C152H222N38O50
- Molecular weight: 3,382 g/mol
- CAS number: 1544300-84-6
- Half-life: About 30 minutes
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 8
- Controlled human trials: 8
- Preclinical sources: 1
- Latest source: 2026

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. ZEGALOGUE (dasiglucagon) injection — FDA prescribing information, revised 06/2026 (Drugs@FDA). 2026. Regulatory label (FDA), human. Population: Adults and children with diabetes who weigh at least 20 kg, for severe hypoglycemia. Rapid rise in blood glucose [Source](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214231s004lbl.pdf)
2. Pieber TR et al. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care. 2021. 2021. Controlled human trial. Population: Adults with type 1 diabetes during controlled insulin-induced hypoglycemia (n=170). Median time to glucose recovery was 10 minutes versus 40 on placebo and 12 with glucagon [Source](https://pubmed.ncbi.nlm.nih.gov/35239971/)
3. Bailey TS et al. Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial. Diabetes Obes Metab. 2021. 2021. Controlled human trial. Population: Adults with type 1 diabetes during controlled hypoglycemia (n=45). Median time to glucose recovery was 10 minutes versus 35 on placebo [Source](https://pubmed.ncbi.nlm.nih.gov/34169625/)
4. Battelino T et al. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial. Pediatr Diabetes. 2021. 2021. Controlled human trial. Population: Children and adolescents aged 6 to 17 with type 1 diabetes (n=42). Median time to glucose recovery was 10 minutes versus 30 on placebo and 10 with glucagon [Source](https://pubmed.ncbi.nlm.nih.gov/33934456/)
5. NCT05378672 — A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D. Controlled human trial. Population: Children under 6 years, above 8 kg, with type 1 diabetes (n=8). Supported the June 2026 change to a 20 kg weight limit; results posted on the registry [Source](https://clinicaltrials.gov/study/NCT05378672)
6. Hövelmann U et al. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care. 2018. 2018. Controlled human trial. Population: Adults with type 1 diabetes during insulin-induced hypoglycemia (n=58). Peak level at about 35 minutes and half-life of about 0.5 hours; early glucose response similar to glucagon [Source](https://pubmed.ncbi.nlm.nih.gov/29273578/)
7. Laugesen C et al. Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial. Diabetologia. 2023. 2023. Controlled human trial. Population: Adults with insulin pump-treated type 1 diabetes (n=24). Faster recovery and 11% less daily carbohydrate intake than usual care [Source](https://pubmed.ncbi.nlm.nih.gov/37037948/)
8. Nielsen CK et al. Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care. 2023. 2023. Controlled human trial. Population: People with hypoglycemia after Roux-en-Y gastric bypass (n=24). Time in level 1 hypoglycemia fell 33% and in level 2 fell 54% versus placebo [Source](https://pubmed.ncbi.nlm.nih.gov/37819999/)
9. Thornton PS et al. Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children. J Clin Endocrinol Metab. 2024. 2024. Controlled human trial. Population: Children aged 0.6 to 10.9 years with congenital hyperinsulinism (n=32). No significant difference on the primary endpoint; post hoc, 43% less hypoglycemia on continuous glucose monitoring [Source](https://pubmed.ncbi.nlm.nih.gov/37930757/)
10. ZEGALOGUE (dasiglucagon) injection — FDA prescribing information, section 8.1 (Drugs@FDA). Preclinical: animal or lab study. Population: Pregnant rats and rabbits. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214231s004lbl.pdf)

### Registered trials

- [NCT05378672](https://clinicaltrials.gov/study/NCT05378672)

## Safety

Side effects: Nausea (57% of adults, 65% of children); Vomiting (25% of adults, 50% of children); Headache (11% of adults, 10% of children); Diarrhea (5% of adults); Injection site pain (2% of adults, 5% of children).

Risks: Contraindicated in pheochromocytoma because it may release catecholamines and sharply raise blood pressure; Contraindicated in insulinoma because it can trigger exaggerated insulin release and later hypoglycemia; Allergic reactions, including anaphylactic shock, have been reported with glucagon products; May not work with low liver glycogen, as in starvation, adrenal insufficiency or chronic hypoglycemia; Interacts with beta-blockers, indomethacin and warfarin; FDA’s Drugs@FDA database lists both presentations as discontinued.

Contraindications: Pheochromocytoma; Insulinoma.

Human safety basis: FDA prescribing information

## Regulatory status

Dasiglucagon is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- Availability: Discontinued

## Frequently asked questions

### What is dasiglucagon?

Dasiglucagon is a rescue medicine for severe low blood sugar, sold as Zegalogue. It is a synthetic 29-amino-acid analog of glucagon, supplied as a ready-to-use injection, so there is no powder to mix during an emergency.

### How does dasiglucagon work?

Dasiglucagon activates glucagon receptors in the liver, which breaks down stored glycogen and releases glucose into the blood. It needs glycogen to work, so it may fail in starvation, adrenal insufficiency or chronic hypoglycemia.

### Is dasiglucagon FDA approved?

Yes. FDA approved Zegalogue on 22 March 2021 (NDA 214231). A June 2026 supplement changed the pediatric limit to children who weigh at least 20 kg. FDA’s Drugs@FDA database now lists both presentations as discontinued, though the approval has not been withdrawn.

### Is Zegalogue still available?

FDA’s Drugs@FDA database lists both Zegalogue presentations as discontinued, and FDA’s NDC directory shows a marketing end date of 31 August 2027 for Novo Nordisk’s listings. Check with a pharmacy for current supply, because these databases do not show stock.

### What compounds are similar to dasiglucagon?

Glucagon is the natural hormone it is based on. Pramlintide and liraglutide are listed alongside it as other diabetes-related peptides, but they act on different receptors and are not rescue medicines.

## References

- [ZEGALOGUE (dasiglucagon) injection — FDA prescribing information, revised 06/2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214231s004lbl.pdf)
- [NDA 214231/S-004 supplement approval letter — FDA, June 2026](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/214231Orig1s004ltr.pdf)
- [ZEGALOGUE (dasiglucagon) injection — DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14704879-872c-4967-8779-04a3bbdfb4e6)
- [Drugs@FDA — NDA 214231](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214231)
- [Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia — Diabetes Care, 2021](https://pubmed.ncbi.nlm.nih.gov/35239971/)
- [Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device — Diabetes Obes Metab, 2021](https://pubmed.ncbi.nlm.nih.gov/34169625/)
- [Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes — Pediatr Diabetes, 2021](https://pubmed.ncbi.nlm.nih.gov/33934456/)
- [Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog — Diabetes Care, 2018](https://pubmed.ncbi.nlm.nih.gov/29273578/)
- [Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children — J Clin Endocrinol Metab, 2024](https://pubmed.ncbi.nlm.nih.gov/37930757/)
- [Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass — Diabetes Care, 2023](https://pubmed.ncbi.nlm.nih.gov/37819999/)

Note: Dose figures are left out of this Markdown version. See the cited sources.